Logo image of RLMD

RELMADA THERAPEUTICS INC (RLMD) Stock Analyst Ratings

NASDAQ:RLMD - Nasdaq - US75955J4022 - Common Stock - Currency: USD

0.2898  0 (-0.75%)

After market: 0.287 0 (-0.97%)

Buy % Consensus

48

ChartMill assigns a Buy % Consensus number of 48% to RLMD. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 0.88. This target is 205.05% above the current price.
RLMD was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about RLMD.
In the previous month the buy percentage consensus was at a similar level.
RLMD was analyzed by 8 analysts. More opinions would make the average more meaningful.

Related screens

RLMD Historical Analyst RatingsRLMD Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -67 -61 -55 -49 -43 -37 -31 -25 -19 -13 -7 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.290.611.020.881.05 - 109.11% 251.97% 205.05% 262.32%

Related screens

RLMD Current Analyst RatingRLMD Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4
Up and Down Grades
Date Firm Action Rating
2024-12-05 Mizuho Downgrade Outperform -> Neutral
2024-12-04 Leerink Partners Downgrade Outperform -> Market Perform
2024-09-17 Jefferies Upgrade Hold -> Buy
2024-06-05 Goldman Sachs Downgrade Neutral -> Sell
2023-06-15 Mizuho Reiterate Buy -> Buy
2023-01-23 SVB Leerink Maintains Outperform
2022-10-14 Guggenheim Downgrade Buy -> Neutral
2022-10-14 Goldman Sachs Downgrade Buy -> Neutral
2022-10-13 Oppenheimer Downgrade Outperform -> Perform
2022-09-23 Goldman Sachs Maintains Buy
2022-09-06 Guggenheim Maintains Buy
2022-05-09 Oppenheimer Maintains Outperform
2021-12-20 SVB Leerink Maintains Outperform
2021-11-18 Mizuho Initiate Buy